Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.
Chen. Kuan-Hsuan KH; Wang. Sheng-Fan SF; Wang. Szu-Yu SY; Yang. Yi-Ping YP; Wang. Mong-Lien ML; Chiou. Sih-Hwa SH; Chang. Yuh-Lih YL
Key Findings
- Thymosin‑alpha‑1 is identified as a potential immunomodulatory adjuvant for COVID‑19
- It is grouped with other agents like IVIG, IL‑6 blockers, and tocilizumab
- The article provides no specific efficacy data, safety details, or dosage recommendations for thymosin‑alpha‑1
Practical Outcomes
- For biohackers, the main takeaway is that thymosin‑alpha‑1 is being investigated but there’s no actionable guidance yet. Until clinical trials publish concrete results, it’s not ready for self‑directed use, and any experimentation should consider unknown safety and dosing.
Summary
The paper is a broad review of drugs that might help treat COVID‑19, and it mentions thymosin‑alpha‑1 as one of several immune‑boosting agents, but it doesn’t give new trial results, dosing advice, or clear protocols for using it.
Abstract
As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α-1, interleukin [IL]-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti-vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins, and nutritional supplements (i.e. vitamins A, B, C, D, E and zinc). This article reviewed the pharmacological development of potential adjuvants for COVID-19 treatment.
Study Information
pubmed
2020
10.1097/jcma.0000000000000375